Generic Triferic Availability

Last updated on Jun 11, 2025.

Triferic is a brand name of ferric pyrophosphate, approved by the FDA in the following formulation(s):

TRIFERIC (ferric pyrophosphate citrate - powder;intravenous)

• Manufacturer: ROCKWELL MEDICAL INC
  Approval date: April 25, 2016
  Strength(s): 272MG IRON/PACKET (discontinued) ^[RLD]

TRIFERIC (ferric pyrophosphate citrate - solution;intravenous)

• Manufacturer: ROCKWELL MEDICAL INC
  Approval date: January 23, 2015
  Strength(s): 27.2MG IRON/5ML (5.44MG IRON/ML) (discontinued) ^[RLD]
• Manufacturer: ROCKWELL MEDICAL INC
  Approval date: September 4, 2015
  Strength(s): 272MG IRON/50ML (5.44MG IRON/ML) (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triferic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
  Patent 7,816,404
  Issued: October 19, 2010
  Inventor(s): McCall, Jr.; William S.
  Assignee(s): Rockwell Medical Technologies, Inc. (Wixom, MI)
  

  A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.

  Patent expiration dates:

  • April 17, 2029
    
    ✓ 
    Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
  • April 17, 2029
    
    ✓ 
    Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
    ✓ 
    Drug product
• Packaging of ferric pyrophosphate for dialysis
  Patent 7,857,977
  Issued: December 28, 2010
  Inventor(s): Wash; Lori L.
  Assignee(s): Rockwell Medical Technologies, Inc. (Wixom, MI)
  

  A stable packaged bicarbonate solution for use in dialysis treatment and for treating anemia, iron deficiency, or reducing the required dose of recombinant erythropoietin to treat anemia includes a bicarbonate solution into which ferric pyrophosphate is dissolved. The amount of ferric pyrophosphate dissolved in the bicarbonate solution is sufficient to provide a therapeutic effect for the treatment of anemia, iron deficiency or to reduce dose of recombinant erythropoietin needed to treat anemia when the bicarbonate solution is combined with other dialysis components to form a dialysate used for dialyzing a patient. The ferric pyrophosphate is stabilized in the bicarbonate solution by holding the solution in a polyolefin container or container liner, such as a high density polyethylene container or liner.

  Patent expiration dates:

  • September 8, 2027
    
    ✓ 
    Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer